Odujinrin v. Comm'r

2014 T.C. Memo. 213, 108 T.C.M. 441, 108 Tax Ct. Mem. Dec. (CCH) 441, 2014 Tax Ct. Memo LEXIS 211
CourtUnited States Tax Court
DecidedOctober 9, 2014
DocketDocket No. 5194-13.
StatusUnpublished
Cited by4 cases

This text of 2014 T.C. Memo. 213 (Odujinrin v. Comm'r) is published on Counsel Stack Legal Research, covering United States Tax Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Odujinrin v. Comm'r, 2014 T.C. Memo. 213, 108 T.C.M. 441, 108 Tax Ct. Mem. Dec. (CCH) 441, 2014 Tax Ct. Memo LEXIS 211 (tax 2014).

Opinion

WOLE ODUJINRIN a.k.a. OLUWOLE OLUMIDE ODUJINRIN, Petitioner v. COMMISSIONER OF INTERNAL REVENUE, Respondent
Odujinrin v. Comm'r
Docket No. 5194-13.
United States Tax Court
T.C. Memo 2014-213; 2014 Tax Ct. Memo LEXIS 211; 108 T.C.M. (CCH) 441;
October 9, 2014, Filed

Decision will be entered under Rule 155.

*211 Wole Odujinrin a.k.a. Oluwole Olumide Odujinrin, Pro se.
Cory H. Ellenson and Kathryn A. Meyer, for respondent.
LAUBER, Judge.

LAUBER
MEMORANDUM FINDINGS OF FACT AND OPINION

LAUBER, Judge: With respect to petitioner's Federal income tax for 2009, the Internal Revenue Service (IRS or respondent) determined a deficiency in tax of *214 $87,761 and a section 6662(a)1 accuracy-related penalty of $17,552. After concessions, the issues for decision are: (1) whether petitioner is entitled to deduct for 2009 a claimed net operating loss (NOL) of $24,368 (we hold that he is not); (2) whether petitioner is entitled to deduct business expenses beyond those that respondent has allowed (with certain exceptions, we hold that he is not); and (3) whether petitioner is liable for the accuracy-related penalty (we hold that he is).

FINDINGS OF FACT

The parties submitted a stipulation of facts at trial. At the close of trial the Court left the record open*212 for 60 days to allow petitioner an opportunity to submit additional documentary evidence substantiating his claimed deductions. On May 6, 2014, the parties timely submitted a partial stipulation of settled issues and a supplemental stipulation of facts. We incorporate the stipulations of facts and the related exhibits by this reference. Petitioner resided in California when he filed his petition.

*215 Petitioner is a hematology oncologist. In 2009 he operated a sole proprietorship through a limited liability company named Customized Therapeutics. Petitioner conducted two lines of business: an oncology medical practice and a business whose goal was to research and develop cancer therapies.

Petitioner conducted his oncology medical practice as a locum tenens physician. As such, he was not permanently assigned to any hospital but rather worked for short-term periods with hospitals that had a temporary need for an oncologist with his skills. During 2009 petitioner had temporary affiliations with four hospitals, all of which were distant from his home. Two of the hospitals were in Yakima, Washington; one was in Eureka, California; and the other was in Hastings, Nebraska.

Petitioner spent one or*213 more months in toto at each location, and he traveled home intermittently. Each hospital reimbursed petitioner for travel and housing expenses allocable to his services for it. Each hospital also paid (or reimbursed petitioner for) malpractice insurance covering his services to it. Petitioner offered no credible testimony concerning the extent to which the hospitals reimbursed him for other expenses (such as meals) or the extent to which he incurred expenses in excess of the amounts reimbursed.

*216 To conduct his cancer research business, petitioner maintained an office in Altadena, California. This office employed one person, Rakesh Penmetsa. His activities included soliciting research grants; contracting with the National Institutes of Health (NIH) for investigation of promising cancer therapies; and otherwise managing the development of petitioner's cancer research.

Petitioner timely filed a Federal income tax return for 2009. On this return he reported income and expenses from both lines of business--his oncology medical practice and his cancer research business--on a single Schedule C, Profit or Loss From Business. This Schedule C reported gross receipts of $300,605 and total expenses*214 of $269,075. These expenses consisted of wages of $59,750; rent or lease expense of $15,000; office expense of $9,425; insurance expense (other than health) of $25,000; meals and entertainment expense of $6,775; travel expense of $63,050; interest expense of $4,811; and "other expenses" of $85,264. Petitioner also claimed an NOL carryforward to 2009 of $24,368.

Section 9023 of the Patient Protection and Affordable Care Act (ACA), Pub. L. No. 111-148, 124 Stat. at 877 (2010), provided Federal funding for a "qualifying therapeutic discovery project" (QTDP). This provision allowed taxpayers to claim a tax credit, codified in section 48D of the Code, or alternatively to apply for a cash grant awarded by the Department of the Treasury *217 in lieu of a credit. This credit or grant, which was effective for 2009, was computed as 50% of a taxpayer's "qualified investment" for such taxable year in a qualifying project. Seesec. 48D; ACA sec. 9023(e)(1), (4), 124 Stat. at 881, 884. An IRS notice informed taxpayers of the procedures governing application for the credit or grant.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Patricia Marcello Anderson
U.S. Tax Court, 2024
William Geiman
U.S. Tax Court, 2021
Wang v. Comm'r
2017 T.C. Memo. 81 (U.S. Tax Court, 2017)
Holden v. Comm'r
2015 T.C. Memo. 83 (U.S. Tax Court, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
2014 T.C. Memo. 213, 108 T.C.M. 441, 108 Tax Ct. Mem. Dec. (CCH) 441, 2014 Tax Ct. Memo LEXIS 211, Counsel Stack Legal Research, https://law.counselstack.com/opinion/odujinrin-v-commr-tax-2014.